Combined central and peripheral demyelination (CCPD) is a rare disease characterized by demyelinating lesions in both the central nervous system (CNS) and peripheral nervous system (PNS). CCPD can present with acute, subacute, or chronic onset. The initial symptom may be of CNS origin, PNS origin, or both. The clinical manifestations of CCPD are quite heterogeneous, and there are no well-defined diagnostic criteria. In MRI imaging of CCPD cases, demyelinating lesions can be seen in areas such as the brain, cerebellum, brainstem, optic nerve, and spinal cord. Common electromyography (EMG) findings in patients with CCPD include decreased motor nerve conduction velocities, decreased or absent sensory nerve action potentials, prolonged F-wave latency, and decreased amplitude of compound muscle action potentials. Neurofascin (NF) is a transmembrane protein and anti-neurofascin (anti-NF) antibodies directed against NF can be positive in cases of CCPD. Four main NF polypeptides are produced by alternative splicing: NF 186, NF 180, NF 166, and NF 155. The investigation of anti-NF in CCPD cases is therefore important for etiological considerations. Here, we discussed three cases diagnosed with CCPD based on clinical, neuroimaging, EMG, and anti-NF antibody results in light of the literature.

1.
Ogata
H
,
Matsuse
D
,
Yamasaki
R
,
Kawamura
N
,
Matsushita
T
,
Yonekawa
T
, et al
.
A nationwide survey of combined central and peripheral demyelination in Japan
.
J Neurol Neurosurg Psychiatry
.
2016
;
87
(
1
):
29
36
. .
2.
Hou
X
,
Liang
Y
,
Cui
P
,
Hao
J
.
The clinical features of combined central and peripheral demyelination and antibodies against the node of Ranvier
.
Mult Scler
.
2022
;
28
(
3
):
453
62
. .
3.
Kawamura
N
,
Yamasaki
R
,
Yonekawa
T
,
Matsushita
T
,
Kusunoki
S
,
Nagayama
S
, et al
.
Anti-neurofascin antibody in patients with combined central and peripheral demyelination
.
Neurology
.
2013
;
81
(
8
):
714
22
. .
4.
Kira
J-I
.
Anti-Neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy/combined central and peripheral demyelination: strategies for diagnosis and treatment based on the disease mechanism
.
Front Neurol
.
2021
;
12
:
665136
. .
5.
Alshamrani
F
,
Alyami
R
,
Alghanimi
I
,
Alajaji
R
,
Alkhaldi
M
,
Alamri
A
.
A new report of combined central and peripheral demyelination: a case report
.
Front Neurol
.
2021
;
12
:
730129
. .
6.
Cortese
A
,
Franciotta
D
,
Alfonsi
E
,
Visigalli
N
,
Zardini
E
,
Diamanti
L
, et al
.
Combined central and peripheral demyelination: clinical features, diagnostic findings, and treatment
.
J Neurol Sci
.
2016
;
363
:
182
7
. .
7.
Nouha
H
,
Olfa
H
,
Nouha
F
,
Sawsan
F
,
Salma
S
,
Hanen
HK
, et al
.
Combined central and peripheral demyelination: a case report and literature review
.
Curr J Neurol
.
2019
;
18
(
1
):
35
7
. .
8.
Van den Bergh
PYK
,
van Doorn
PA
,
Hadden
RDM
,
Avau
B
,
Vankrunkelsven
P
,
Allen
JA
, et al
.
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force – second revision
.
Eur J Neurol
.
2021
;
28
(
11
):
3556
83
. .
9.
McNicholas
N
,
Hutchinson
M
,
McGuigan
C
,
Chataway
J
.
2017 McDonald diagnostic criteria: a review of the evidence
.
Mult Scler Relat Disord
.
2018
;
24
:
48
54
. .
You do not currently have access to this content.